- Home
- ESAB vs NUVL Comparison
ESAB vs NUVL Comparison
Compare ESAB & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- NUVL
- Stock Information
- Founded
- ESAB 1904
- NUVL 2017
- Country
- ESAB United States
- NUVL United States
- Employees
- ESAB N/A
- NUVL 218
- Industry
- ESAB Office Equipment/Supplies/Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ESAB Industrials
- NUVL Health Care
- Exchange
- ESAB Nasdaq
- NUVL Nasdaq
- Market Cap
- ESAB 6.6B
- NUVL 7.2B
- IPO Year
- ESAB N/A
- NUVL 2021
- Fundamental
- Price
- ESAB $114.63
- NUVL $92.97
- Analyst Decision
- ESAB Strong Buy
- NUVL Strong Buy
- Analyst Count
- ESAB 8
- NUVL 12
- Target Price
- ESAB $143.38
- NUVL $123.33
- AVG Volume (30 Days)
- ESAB 462.7K
- NUVL 572.6K
- Earning Date
- ESAB 10-29-2025
- NUVL 10-30-2025
- Dividend Yield
- ESAB 0.35%
- NUVL N/A
- EPS Growth
- ESAB N/A
- NUVL N/A
- EPS
- ESAB 3.95
- NUVL N/A
- Revenue
- ESAB $2,792,325,000.00
- NUVL N/A
- Revenue This Year
- ESAB $0.85
- NUVL N/A
- Revenue Next Year
- ESAB $6.26
- NUVL N/A
- P/E Ratio
- ESAB $29.25
- NUVL N/A
- Revenue Growth
- ESAB 1.19
- NUVL N/A
- 52 Week Low
- ESAB $100.17
- NUVL $55.54
- 52 Week High
- ESAB $135.97
- NUVL $104.90
- Technical
- Relative Strength Index (RSI)
- ESAB 43.52
- NUVL 52.17
- Support Level
- ESAB $110.30
- NUVL $90.00
- Resistance Level
- ESAB $122.20
- NUVL $104.90
- Average True Range (ATR)
- ESAB 3.34
- NUVL 5.39
- MACD
- ESAB -0.89
- NUVL -0.04
- Stochastic Oscillator
- ESAB 30.86
- NUVL 40.05
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.